Group | Activity-NaF | Total activity+NaF |
|---|
Control | 12.36 | 9.30 |
Lovastatin | 13.34 | ND |
Gl (2.5%) | 5.86a | 2.66a |
Gl (5%) | 8.08a | 4.86a |
- Refer to the text for methodologic details. [14C]mevalonate was converted to [14C]mevalonolactone with 10 M HCl before the TLC step. Values above were corrected for recovery (15–63%) with [3H]mevalonate. G. lucidum, but not lovastatin, was found to inhibit ex vivo synthesis whether: recovery was accounted for; results were expressed per gram liver weight; [14C]mevalonolactone was first extracted into organic solvent and then applied to TLC plates [79] rather than applying aqueous extracts directly to TLC plates [55] as reported above (data not shown); and whether or not endogenous phosphatase activity was inhibited with 50 mM NaF (shown above). Values represent mean of 6 determinations. aSignificantly different from control, students unpaired, 2-tailed t-test, equal variances (P < 0.05). ND, not determined.
